{
    "clinical_study": {
        "@rank": "112809", 
        "acronym": "bioSAB", 
        "arm_group": [
            {
                "arm_group_label": "SAB analysis", 
                "arm_group_type": "Experimental", 
                "description": "Patients with acute aneurysmal SAH, confirmed by CT or MRI, or lumbar puncture\nDaily (21 days) analysis of Biomarker in serum, in liquor and in micro-dialysate"
            }, 
            {
                "arm_group_label": "Control", 
                "arm_group_type": "Experimental", 
                "description": "Patients who undergo a lumbar puncture for myelography as part of the investigation of a cervical or lumbar foraminal stenosis without cranial or myel\u00e4re pathology -or- Patients who receive perioperative prophylactic lumbar drainage without cranial or myel\u00e4re pathology\nSingle analysis of Biomarker in serum and liquor"
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of this study is to improve the usability of biomarkers for the timely prediction of\n      new complications following a cerebral hemorrhage, especially in combination with invasive,\n      functional and local measurements for patients with aneurysmal subarachnoid hemorrhage\n      (SAH). Based on analyzed biomarker profiles the chosen therapy efforts are assessed in their\n      immediate and longer-term effectiveness."
        }, 
        "brief_title": "The Role of Biomarker in Serum, Cerebrospinal Fluid and Parenchyma in the Context of Aneurysmal Subarachnoid Hemorrhage.", 
        "completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Aneurysmal Subarachnoid Hemorrhage", 
        "condition_browse": {
            "mesh_term": [
                "Hemorrhage", 
                "Subarachnoid Hemorrhage"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  male or female, age \u2265 18 years\n\n          -  signed consent for participation in the study\n\n          -  signed consent for further analysis of the samples collected during the clinical\n             routine\n\n          -  in-patients\n\n        Exclusion Criteria:\n\n          -  female or male patient <18 years\n\n          -  pregnancy, lactation\n\n          -  lack of signed informed consent for participation in the study\n\n          -  lack of signed consent for the further analysis of the samples collected during the\n             clinical routine\n\n          -  taking a study drug within the last thirty days\n\n          -  Simultaneous participation in another clinical trial (except participation as control\n             group)\n\n          -  persons who are in a dependent relationship or employment with the sponsor or\n             investigator\n\n          -  persons housed for a judicial or administrative order in an institution"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 30, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02142166", 
            "org_study_id": "CTC-A 14-004"
        }, 
        "intervention": [
            {
                "arm_group_label": "SAB analysis", 
                "description": "Daily (21 days) analysis of biomarker in serum, in liquor and in micro-dialysate", 
                "intervention_name": "Biomarker in serum, liquor, micro-dialysate", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": "Control", 
                "description": "Single analysis of biomarker in serum and liquor", 
                "intervention_name": "Biomarker in serum and in liquor", 
                "intervention_type": "Procedure"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "aneurysmal subarachnoid hemorrhage (ASH)", 
            "biomarker"
        ], 
        "lastchanged_date": "May 19, 2014", 
        "location": {
            "contact": {
                "email": "gschubert@ukaachen.de", 
                "last_name": "Gerrit A. Schubert, PD. Dr.", 
                "phone": "+492418088481"
            }, 
            "facility": {
                "address": {
                    "city": "Aachen", 
                    "country": "Germany", 
                    "state": "NRW", 
                    "zip": "52074"
                }, 
                "name": "Department of Neurosurgery, University Hospital RWTH Aachen"
            }, 
            "investigator": [
                {
                    "last_name": "Gerrit A. Schubert, PD. Dr.", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Walid Albanna, Dr.", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "Die Rolle Der Biomarker in Serum, Liquor Und Parenchym im Rahmen Der Aneurysmatischen Subarachnoidalblutung: Verlauf Und Korrelation zu Therapie Und Outcome - bioSAB -", 
        "overall_contact": {
            "email": "gschubert@ukaachen.de", 
            "last_name": "Gerrit A. Schubert, PD. Dr.", 
            "phone": "+492418088481"
        }, 
        "overall_official": {
            "affiliation": "Department of Neurosurgery, University Hospital RWTH Aachen", 
            "last_name": "Gerrit A. Schubert, PD. Dr.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Ethics Commission", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Temporal development of alternative biomarkers in serum, cerebrospinal fluid and parenchyma after aneurysmal SAH, and their response as influenced by the treatment path.", 
            "measure": "Biomarker in serum, cerebrospinal fluid and parenchyma after aneurysmal SAH", 
            "safety_issue": "No", 
            "time_frame": "Each participant will be followed at hospital stay for an expected average of 3 weeks. The outcome measure will be assessed after 24 month."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02142166"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "RWTH Aachen University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "RWTH Aachen University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}